Cellular Reprogramming, Inc. provides rapid, low-cost, footprint-free derivation of induced pluripotent stem cells (iPSCs) from human fibroblasts on a fee-for-service basis. Our service uses an advanced form of messenger RNA reprogramming, the fastest, most efficient and most clinically-relevant method of converting fibroblasts to pluripotent stem cells yet devised.
Cellular Reprogramming, Inc. performs footprint-free iPSC derivations on human fibroblasts on a fee-for-service basis. Our team has experience making hundreds of patient-specific lines for clients in pharma and academia. The company’s iPSC derivation pipeline is based on an advanced form of mRNA reprogramming that affords the fastest and most efficient method of converting human fibroblasts into pluripotent stem cells yet devised.
We charge $2000 per line for reprogramming, comprising a non-refundable $500 upfront payment and an on-delivery balance of $1500. Our minimum order is 10 lines ($5K down). Shipping costs are the responsibility of the customer.
Customers should submit a cryovial with ~500K human fibroblasts for each line to be reprogrammed, and must warrant that the submitted cells have tested negative for mycoplasma contamination.
We supply 3 x 1ml replicate cryostocks of iPSCs for each delivered line. We recommend plating the contents of a vial to a single 6-well format well or split between two such wells in 1:2 ratio. Note that we do not offer multiple putative iPSC “clones” isolated by colony picking as we bulk passage nascent colonies from reprogramming plates to establish our passage 1 iPSC cultures. The bulk passaging method is increasingly a preferred practice when using the highly efficient and inherently non-clonal mRNA reprogramming system.
Each iPSC line is delivered with a datasheet presenting phase contrast images and DAPI/OCT4/TRA-1-60 immunostaining demonstrating iPSC morphology and generalized expression of canonical molecular markers. We do not offer functional characterization as a standard service.
Internally, we expand and stabilize iPSCs in the Nutristem/rLN521 culture system. Our customers using other media/substrate combinations report that the cells we provide usually adapt readily on being directly plated in their preferred system. However, recovering to Nutristem/rLN521 first and then transitioning to the in-house culture system is the best approach and should always be considered as a fallback option.
Most of the lines we reprogram spend about a month in culture, from the thawing of the fibroblasts to iPSC freezedown at p3 or later. Overall turnaround time is typically about 45-60 days, allowing for the time required to bring batches of lines into culture and the fact that a minority of lines require extra passages before being release-ready in terms of homogeneity and stability. Turnaround can be affected by other factors including our current workload. Customers with specific time constraints should contact us to discuss timelines before ordering. Work queue priority is determined by the date of purchase order receipt, so long as we have input cells in hand.
Please note that we cannot guarantee a successful iPSC derivation from every line submitted. In general, slow-growing, late-passage lines tend to do less well in reprogramming. Our historical success rate on low-passage (p3-p5) dermal fibroblasts is 90-100%. While we have often attained high success rates even with lower quality material, note that our accelerated, feeder-free reprogramming protocol is not optimized for dealing with aged or refractory fibroblast lines.
We provide iPSCs for research use only (RUO). Any diagnostic or therapeutic use of the iPSCs or their derivatives by the customer or a direct or indirect transferee is strictly prohibited. As a condition of sale, customers agree to be bound by these restrictions and to bind any direct or indirect transferee accordingly. Resale of the iPSCs or their derivatives is prohibited without the written authorization of Cellular Reprogramming, Inc.
Cellular Reprogramming, Inc. has not received any reviews.
I am the director of the Cellular Neuropsychiatry Laboratory at McLean Hospital. Our lab has reprogrammed 20 subject lines through Cellular Reprogramming. We have had great success with expanding all of these lines and have found them stable over passaging. We have also used a number of the Cellular Reprogramming lines in an oligodendrocyte differentiation protocol that involves differentiation of over 85 days. In this complex differentiation we find that the Cellular Reprogramming lines behave in a manner similar or better than lines reprogrammed from other sources. Additional pluses are that the cost of the process is very reasonable and that they have excellent customer service. I will definitely be sending more lines to Cellular Reprogramming and I strongly recommended Cellular Reprogramming to colleagues.
Our lab has reprogrammed more than twenty lines for the last couple of years through Cellular Reprogramming, Inc. and had excellent experience with them. They delivered quality product within a give time line and backed their product with excellent customer support. For example, they re-reprogrammed failed lines free of charge and in rare case when their stock does not revive well, they were willing to provide replacement stocks. All their lines are very stable over extended passaging and well maintained their differentiation potential. Their pricing was very reasonable and all our questions were answered in a timely manner. Based on our excellent experience we had, I strongly recommend Cellular Reprogramming, Inc to other investigators for their reprogramming needs.
I am a Principal Faculty Member at the Harvard Stem Cell Institute, based at Brigham and Women's Hospital in Boston. Recently, we reprogrammed approximately 20 fibroblast lines to iPSc with Cellular Reprogramming, Inc. I would highly recommend their services. Luigi Warren was professional, personable and delivered on his word. Stated timelines for the work orders were met, and the entire process was efficient and stress-free. Moreover, as has been noted by others, costing was highly competitive and highly enabling for our projects. Reprogramming was achieved for all lines, with only a couple of lines requiring a second attempt (at no extra cost to us). So far, all the resultant lines we have thawed have thawed out easily, exhibited normal karyotype and have readily differentiated into neurons. Clients should be aware that the iPSc lines from Cellular Reprogramming are polyclonal, and understand the implications of that. Typically, after genome editing, our lab subclones out lines, and so beginning with a polyclonal population is immaterial. While polyclonal lines might theoretically be expected to drift with multiple passages, they also avoid potential reprogramming biases originating from single fibroblasts. In any case, as noted above, subcloning is straightforward if desired. In sum, Cellular Reprogramming offers a terrific service to generate iPSc with a standard (mRNA-based) non integrating method. Their highly competitive pricing is enabling for larger scale projects, and they have been a pleasure to deal with. I would highly recommend them to anyone in academia or industry.
I direct the Platform for Cellular Modeling of Neuropsychiatric Disease at Massachusetts General Hospital in the Center for Genomic Medicine. The goal of our program is to develop cellular models of neuropsychiatric patients from a large bank of collected fibroblasts obtained from skin biopsy. We enlisted Cellular Reprogramming Inc. (CRI) to pilot the first 50 lines. Unlike other companies that perform this service, CRI quoted us a fraction of the cost (one company quoted us 8 times more for the same job, typical is 6-10X more) and a quicker turn around time than other companies quoted times. Since that initial pilot, CRI has now reprogrammed 260+ high quality iPSC lines for us under our original budget for just a few dozen and much faster than we had anticipated. I have now recommended CRI to several colleagues, from academia to large pharma, who have used them as well with the same positive results.